Regulatory Insights

  1. What Does The FDA's 2025 Safety Reporting Guidance Mean For You? 4/6/2026

    New FDA guidance aligns IND safety reports with unanticipated problems, shifting the focus from administrative definitions to proactive participant protection and trial integrity.

  2. Paper COAs In 2026? It's Not "Cheaper," It's Riskier 4/1/2026

    Paper-based assessments add operational and regulatory risk — from poor data quality to delayed insights — quietly threatening timelines, compliance, and trial confidence.

  3. Strategies To Win Breakthrough Designation In Rare Disease Programs 3/31/2026

    Breakthrough designation can unlock faster paths for rare disease therapies. Learn how smart timing, compelling evidence, and early regulatory alignment can turn promising science into accelerated patient impact.

  4. 5 RWE Approaches That Strengthen Precision Oncology 3/31/2026

    Real-world evidence is becoming vital in precision oncology. Discover five creative, practical ways sponsors can use RWE to fuel development, sharpen regulatory strategy, and strengthen market access.

  5. Which FIH Decisions Are Hardest To Reverse Later? 3/31/2026

    Early oncology trial decisions can lock in risk, shape regulatory confidence, and limit flexibility. Knowing which choices are hardest to reverse protects optionality and credibility.

  6. Medical Device Clinical Trials: Key Considerations For Sponsors And CROs 3/30/2026

    Medical device trials must align risk class, regulations, and study design. Strong oversight, data, and proactive safety planning support reliable evidence and market approval.

  7. A Guide To Medical Coding In Clinical Trials 3/30/2026

    Medical coding transforms free-text clinical data into standardized terminology, enabling consistent analysis, safety monitoring, and regulatory review. Clear guidelines and quality control help reduce variability and protect data integrity across the entire clinical trial lifecycle.

  8. Mastering Precision Oncology Start-Up: Reducing Screening Delays 3/30/2026

    Biomarker-driven trials create intricate screening hurdles. Explore creative, practical ways to accelerate start‑up, boost enrollment, and power precision oncology studies forward with greater speed.

  9. A New Era Of ADC Development Demands A New Kind Of Partner 3/30/2026

    Explore how to navigate the evolution of antibody-drug conjugates by mastering AI-driven selection, dose optimization, and new regulatory strategies for earlier-line clinical success.

  10. Stay Audit-Ready: Practical Compliance Insights For Research Sites 3/26/2026

    Gain an auditors insight into common compliance gaps and learn practical ways to strengthen audit readiness in sIRB studies.